Table IV.
Univariate survival analysis of cyclin-dependent kinase inhibitor 2A in patients stratified by primary site and stage.
| Overall survival rate | Disease-free survival rate | ||||||
|---|---|---|---|---|---|---|---|
| Stratification factors | RR | 95% CI | P-value | RR | 95% CI | P-value | |
| Primary site | – | – | – | – | – | – | |
| Oral cancer | 0.42 | 0.20–0.88 | 0.017 | 0.52 | 0.28–0.97 | 0.036 | |
| Larynx cancer | 0.56 | 0.20–1.54 | 0.257 | 0.42 | 0.19–0.93 | 0.029 | |
| Primary stage | – | – | – | – | – | – | |
| I/II | 0.25 | 0.10–0.65 | 0.004 | 0.48 | 0.25–0.90 | 0.018 | |
| III/IV | 1.01 | 0.46–2.21 | 0.972 | 1.02 | 0.51–2.05 | 0.953 | |
RR, relative risk; CI, confidence interval.